Project Grant K08HL177337
- The federal Project Grant award of $760,374 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research by National Jewish Health to develop predictive molecular signatures for diagnosing sarcoidosis and identifying patients at risk of disease progression. The project will integrate single nucleotide polymorphisms, gene expression, and plasma metabolomics/lipidomics data using advanced machine learning to identify potential biomarkers....
- The National Heart, Lung, and Blood Institute awarded a $249,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to National Jewish Health to identify common and distinct metabolic and proteomic pathways associated with inflammation and fibrosis in pulmonary sarcoidosis. The 2-year project aims to use plasma specimens to characterize metabolic and proteomic profiles that differentiate fibrotic and non-fibrotic pulmonary sarcoidosis phenotypes and endotypes. This...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $778,266 to the Oklahoma Medical Research Foundation (OMRF) to conduct comprehensive research on sarcoidosis. The key objectives are to: Distinguish sarcoidosis patients from healthy and other immune-mediated disease controls using high-throughput plasma proteomics on over 2,000 participants. Identify biomarkers to distinguish sarcoidosis patients with...
- This Project Grant award of $796,189.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Illinois to define the dynamics of neutrophil subpopulations and their role in inflammatory lung injury and repair. The study aims to identify the distinct functions of the CXCR2 and CXCR4 chemokine receptors in regulating neutrophil trafficking and activation during acute lung inflammation, with the goal of developing...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $451,734 to The University of Iowa to conduct research on the role of residential bioaerosol exposure in pulmonary sarcoidosis. The project aims to determine the association between residential bioaerosol exposure and the severity of pulmonary sarcoidosis, investigate the impact of bioaerosol on immune dysregulation in fibrotic...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance precision medicine for Acute Respiratory Distress Syndrome (ARDS) and sepsis. The $2,295,984 award to the University of California, San Francisco (UCSF) will fund research to address critical unanswered questions about the distinct molecular phenotypes of ARDS and sepsis, and how to optimize real-time phenotyping and integrate analyses of phenotype-specific...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $760,759 to the University of Illinois to examine the immunoregulatory role of a specific dendritic cell subset, CX3CR1+CDC2, in allergic lung inflammation. The project aims to characterize the anti-inflammatory functions of this cell population and its impact on regulatory T cell development and the resolution of allergic asthma symptoms. Through the use of novel...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $759,983.00 to the University of North Carolina at Chapel Hill to conduct research on the role of neutrophils in lung infections and acute lung injury. The study aims to examine changes in neutrophil transcriptomes and function during Streptococcus pneumoniae pneumonia, with the goal of improving understanding of the lung's immune response and potential...
- The University of Washington received a $663,578 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 15, 2025 through May 31, 2029, supports research to better diagnose and understand cardiac sarcoidosis, a form of inflammatory cardiomyopathy. The project aims to "perform 'deep phenotyping' with genetic testing, PET imaging, metabolomic studies, and voltage-guided endomyocardial...
This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $173,480.00 to the University of Illinois to elucidate the mechanisms through which circulating CD14+ monocytes drive the inflammatory-fibrotic axis of advanced pulmonary sarcoidosis-related fibrosis (APSF). The award aims to use single-cell RNA sequencing and surface protein indexing to identify key regulators and signaling pathways within subpopulations of CD14+ monocytes in individuals with chronic sarcoidosis, with and without APSF. Key transcription factors identified will be further tested in an in vitro functional assay of monocyte-to-fibrocyte differentiation to confirm their profibrotic effects. The project also seeks to define the external profibrotic influences monocytes receive from TCM cells. The award period runs from September 2025 through August 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $173.5k | 9/20/25 |